File size: 8,110 Bytes
a90c70e | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 | {
"labels": [
"1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING",
"1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES",
"1.3 CHEMICAL AND PHYSICAL SCIENCES",
"1.4 METHODOLOGIES AND MEASUREMENTS",
"1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)",
"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS",
"2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT",
"2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS",
"2.4 SURVEILLANCE AND DISTRIBUTION",
"2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)",
"2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)",
"3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING",
"3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS",
"3.3 NUTRITION AND CHEMOPREVENTION",
"3.4 VACCINES",
"3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)",
"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES",
"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES",
"4.3 INFLUENCES AND IMPACT",
"4.4 POPULATION SCREENING",
"4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)",
"5.1 PHARMACEUTICALS",
"5.2 CELLULAR AND GENE THERAPIES",
"5.3 MEDICAL DEVICES",
"5.4 SURGERY",
"5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES",
"5.6 PSYCHOLOGICAL AND BEHAVIOURAL",
"5.7 PHYSICAL",
"5.8 COMPLEMENTARY",
"5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)",
"6.1 PHARMACEUTICALS",
"6.2 CELLULAR AND GENE THERAPIES",
"6.3 MEDICAL DEVICES",
"6.4 SURGERY",
"6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES",
"6.6 PSYCHOLOGICAL AND BEHAVIOURAL",
"6.7 PHYSICAL",
"6.8 COMPLEMENTARY",
"6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)",
"7.1 INDIVIDUAL CARE NEEDS",
"7.2 END OF LIFE CARE",
"7.3 MANAGEMENT AND DECISION MAKING",
"7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)",
"8.1 ORGANISATION AND DELIVERY OF SERVICES",
"8.2 HEALTH AND WELFARE ECONOMICS",
"8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE",
"8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)",
"8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)"
],
"label2id": {
"1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING": 0,
"1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES": 1,
"1.3 CHEMICAL AND PHYSICAL SCIENCES": 2,
"1.4 METHODOLOGIES AND MEASUREMENTS": 3,
"1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)": 4,
"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS": 5,
"2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT": 6,
"2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS": 7,
"2.4 SURVEILLANCE AND DISTRIBUTION": 8,
"2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)": 9,
"2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)": 10,
"3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING": 11,
"3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS": 12,
"3.3 NUTRITION AND CHEMOPREVENTION": 13,
"3.4 VACCINES": 14,
"3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)": 15,
"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES": 16,
"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES": 17,
"4.3 INFLUENCES AND IMPACT": 18,
"4.4 POPULATION SCREENING": 19,
"4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)": 20,
"5.1 PHARMACEUTICALS": 21,
"5.2 CELLULAR AND GENE THERAPIES": 22,
"5.3 MEDICAL DEVICES": 23,
"5.4 SURGERY": 24,
"5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES": 25,
"5.6 PSYCHOLOGICAL AND BEHAVIOURAL": 26,
"5.7 PHYSICAL": 27,
"5.8 COMPLEMENTARY": 28,
"5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)": 29,
"6.1 PHARMACEUTICALS": 30,
"6.2 CELLULAR AND GENE THERAPIES": 31,
"6.3 MEDICAL DEVICES": 32,
"6.4 SURGERY": 33,
"6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES": 34,
"6.6 PSYCHOLOGICAL AND BEHAVIOURAL": 35,
"6.7 PHYSICAL": 36,
"6.8 COMPLEMENTARY": 37,
"6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)": 38,
"7.1 INDIVIDUAL CARE NEEDS": 39,
"7.2 END OF LIFE CARE": 40,
"7.3 MANAGEMENT AND DECISION MAKING": 41,
"7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)": 42,
"8.1 ORGANISATION AND DELIVERY OF SERVICES": 43,
"8.2 HEALTH AND WELFARE ECONOMICS": 44,
"8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE": 45,
"8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)": 46,
"8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)": 47
},
"id2label": {
"0": "1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING",
"1": "1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES",
"2": "1.3 CHEMICAL AND PHYSICAL SCIENCES",
"3": "1.4 METHODOLOGIES AND MEASUREMENTS",
"4": "1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)",
"5": "2.1 BIOLOGICAL AND ENDOGENOUS FACTORS",
"6": "2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT",
"7": "2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS",
"8": "2.4 SURVEILLANCE AND DISTRIBUTION",
"9": "2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)",
"10": "2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)",
"11": "3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING",
"12": "3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS",
"13": "3.3 NUTRITION AND CHEMOPREVENTION",
"14": "3.4 VACCINES",
"15": "3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)",
"16": "4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES",
"17": "4.2 EVALUATION OF MARKERS AND TECHNOLOGIES",
"18": "4.3 INFLUENCES AND IMPACT",
"19": "4.4 POPULATION SCREENING",
"20": "4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)",
"21": "5.1 PHARMACEUTICALS",
"22": "5.2 CELLULAR AND GENE THERAPIES",
"23": "5.3 MEDICAL DEVICES",
"24": "5.4 SURGERY",
"25": "5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES",
"26": "5.6 PSYCHOLOGICAL AND BEHAVIOURAL",
"27": "5.7 PHYSICAL",
"28": "5.8 COMPLEMENTARY",
"29": "5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)",
"30": "6.1 PHARMACEUTICALS",
"31": "6.2 CELLULAR AND GENE THERAPIES",
"32": "6.3 MEDICAL DEVICES",
"33": "6.4 SURGERY",
"34": "6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES",
"35": "6.6 PSYCHOLOGICAL AND BEHAVIOURAL",
"36": "6.7 PHYSICAL",
"37": "6.8 COMPLEMENTARY",
"38": "6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)",
"39": "7.1 INDIVIDUAL CARE NEEDS",
"40": "7.2 END OF LIFE CARE",
"41": "7.3 MANAGEMENT AND DECISION MAKING",
"42": "7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)",
"43": "8.1 ORGANISATION AND DELIVERY OF SERVICES",
"44": "8.2 HEALTH AND WELFARE ECONOMICS",
"45": "8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE",
"46": "8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)",
"47": "8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)"
},
"optimal_thresholds": [
0.45000000000000007,
0.50000000000000013,
0.1,
0.30000000000000004,
0.3500000000000001,
0.7500000000000002,
0.4500000000000001,
0.25000000000000006,
0.8000000000000002,
0.40000000000000013,
0.15000000000000002,
0.9000000000000002,
0.20000000000000004,
0.25000000000000006,
0.9000000000000002,
0.40000000000000013,
0.50000000000000013,
0.7500000000000002,
0.25000000000000006,
0.8500000000000002,
0.9000000000000002,
0.30000000000000004,
0.3500000000000001,
0.7500000000000002,
0.20000000000000004,
0.5500000000000002,
0.3500000000000001,
0.1,
0.5,
0.1,
0.8000000000000002,
0.45000000000000007,
0.7000000000000002,
0.3500000000000001,
0.8000000000000002,
0.8000000000000002,
0.6500000000000001,
0.9000000000000002,
0.25000000000000006,
0.25000000000000006,
0.5500000000000002,
0.6000000000000002,
0.25000000000000006,
0.8000000000000002,
0.3500000000000001,
0.4000000000000006,
0.45000000000000007,
0.6500000000000001
],
"base_model_name": "grants_biomedbert",
"max_len": 512
} |